Jill Wechsler, Pharm Exec's Washington Correspondent
Jill Wechsler is Pharm Exec's Washington Corespondent
Pharmaceutical Executive
April 21, 2016.
The good news about FDA’s breakthrough drug initiative is that it actually appears to be accelerating clinical development of highly promising new therapies, according to recent analysis by Friends of Cancer Research (FOCR) .
